New drug could delay breast cancer return in High-Risk patients
NCT ID NCT07242352
First seen Nov 21, 2025 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests if a newer hormone therapy called elacestrant, with or without another drug, works better than standard hormone therapy to prevent breast cancer from coming back. It includes 1520 people with high-risk HR+/HER2- early breast cancer. Participants will take the assigned treatment for up to 7.5 years, and researchers will track cancer recurrence over 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus
RECRUITINGMönchengladbach, North Rhine-Westphalia, 41061, Germany
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.